Skip to main content
Andrew Gelven, DO, Orthopaedic Surgery, Wentzville, MO

Andrew Thomas Gelven DO

Hand Surgery, Orthopedic Sports Medicine


SSM Orthopedics/ Orthopedic Surgeon

Join to view full profile
  • 1601 Wentzville PkwySte 130Wentzville, MO 63385

  • Phone+1 636-332-8455

Dr. Gelven is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Atlanta Sports Medicine Foundation
    Atlanta Sports Medicine FoundationFellowship, Orthopaedic Sports Medicine, 2011 - 2012
  • St Luke's Des Peres Hospital
    St Luke's Des Peres HospitalResidency, Orthopaedic Surgery, 2007 - 2011
  • A. T. Still University Kirksville College of Osteopathic Medicine
    A. T. Still University Kirksville College of Osteopathic MedicineClass of 2005

Certifications & Licensure

  • MO State Medical License
    MO State License 2006 - 2027
  • GA State Medical License
    GA State License 2011 - 2014
  • Orthopedic Surgery
    AOA Board of Orthopedic Surgery Orthopedic Surgery

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
  • CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017

Publications & Presentations

Books/Book Chapters

Grant Support

  • The Role of Ischemia Reperfusion Injury in Lung Allograft RejectionWASHINGTON UNIVERSITY2009–2030
  • Organ donor circadian clocks in transplantation acceptanceWASHINGTON UNIVERSITY2024–2028
  • A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung TransplantationUNIVERSITY OF UTAH2023–2028
  • PET Tracer for Imaging of Lung InflammationWASHINGTON UNIVERSITY2023–2027
  • A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung TransplantationUNIVERSITY OF UTAH2023–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: